Over the past year, shares of Biogen (NASDAQ: BIIB) have dropped by 13.25% while the S&P 500 has climbed by 23.74%. The biotech's poor performance might come as a bit of a surprise since last year its Alzheimer's disease (AD) drug Aduhelm became the first medicine approved in the U.S. for the illness since 2003. Do the company's recent woes represent a buying opportunity or should investors stay away?
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting